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Abstract 
 
The main goal of this thesis is the development of an ophthalmic biodegradable 
insert containing fluocinolone acetonide (FA), to apply in the posterior segment of the 
eye. The inserts under study were prepared using the hot-melt extrusion technique 
(HME). In a previous study, an insert based on hydroxypropyl cellulose (HPC-FA) 
was selected as the best with respect to a wide range of devices tested. New inserts 
containing amylo-maize starch N-400 (AMYLO), corn starch (CS) or corn starch with 
magnesium stearate (CS-MS) were prepared. All inserts were added of 3% FA 
(AMYLO-FA, CS-FA and CS-MS-FA, respectively). Swelling and dissolution 
properties of the new inserts were analysed in isotonic buffer saline (PBS) by a visual 
examination. During the examination time (up to 12 days), AMYLO-FA produced no 
changes in terms of dissolution and gel-like transformation in addition to an initial 
hydration and light swelling compared to the inserts containing CS; so it has 
appeared the most suitable for further studies.  
The physicochemical characteristics of the selected inserts (HPC-FA and 
AMYLO-FA) were determined by a) in vitro drug release and by b) differential 
scanning calorimetry (DSC). Drug release performance of AMYLO-FA and HPC-FA 
inserts was comparatively evaluated using Gummer-type diffusion cells up to 52h, 
maintaining the sink conditions (continuous receiving phase replacement), to evaluate 
the device influence on the FA release independently to the surrounding environment. 
During the time observed, HPC-FA released the drug too quickly (89% of drug 
released) for our goal unlike AMYLO-FA that showed a remarkable reduction of FA 
release (36.13%). The test on AMYLO-FA was continued for 8 days and a slow but 
continuous release was obtained to reach 63.66% of FA at the end of the experiment. 
A controlled drug delivery with zero order kinetics could be hypothesized when 
AMYLO-FA release process reached the steady-state. The release rate of FA from 
AMYLO-FA insert was also determined when the receiving phase (PBS) was totally 
replaced every 24h and 48h simulating the biological conditions:  vitreous humor 
turnover is considered stagnant. For both performed experiment protocols FA release 
from AMYLO-FA insert was linear during the 25-day sampling period but the release 
rate decreased by half for sampling 48 hours. Then it would seem that the release of 
the drug from the device was mainly influenced and driven by the receiving 
environment rather than from the insert.  
    
	   	   	  
The DSC analysis of AMYLO-FA (as physical mixture and extruded) suggested 
that no polymer-drug interaction occurred using the HME and this means that the 
release of the drug might depend only on the modified polymer structure.  
The second part of this thesis aimed at tuning up cylindrical matrices by freeze-
drying for administration of vancomycin (VA) in the precorneal area to produce a 
sustained release of drug and consequently to reduce the number of applications. 
The matrices prepared contained hydroxypropyl methylcellulose (HPMC) and VA in 
ratio 0.25 to 1 and were subjected to a) in vitro release study and b) DSC analysis. 
HPMC-VA matrix released the drug very slowly for our goal, may be due to a drug-
polymer interaction during the freeze-drying process. DSC analysis of lyophilized 
matrix and the single components would suggest this hypothesis.  
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1. The Anatomy and Physiology of the Eye 
 
Figure 1 - The anatomy of the eye. 
 
The eye is an isolated sensory organ and is located in the front upper part of the skull. 
The outer tissues of the eye consist in three layers. The outermost layer consists of 
the cornea and sclera (fibrous tunica), which provide protection for internal structures. 
The middle coat, the uveal tract, is a vascular layer, which has a nutritive function and 
is composed by choroid, ciliary body and the iris. The innermost layer is the retina 
(nervous tunica) containing photoreceptors and is involved in the reception of visual 
stimuli. The inner eye is divided by the lens, which separates the aqueous and 
vitreous humours; instead, the iris separates the aqueous humor into the anterior and 
posterior chambers. A brief description of the eye structures is shown below starting 
from the outside: 
 
a. The Precorneal Tear Film. The precorneal tear film is a very thin layer, 
which is continuously wetting the corneal epithelium, the conjunctiva and the walls of 
the conjunctival cul-de-sac. The tear film has many functions, i.e., provides a smooth 
uniform refractive surface, lubricates the ocular surface, protects against bacterial 
infection, and removes cellular debris and foreign matter. This moisturizing action is 
important not only for the maintenance of a clear cornea but also for the eyelids 
movement.  
  The tear film is composed by three layers: lipid, aqueous, mucin coats. The 
outermost layer is the lipid layer which is approximately 0.1 µm thick and is composed 
by wax and cholesterol; its function is to reduce the evaporation from the underlying 
aqueous phase and, in this way, preventing the cornea from drying out. The aqueous 
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layer lies below the lipid layer and is the larger component of the tear film (6-10 µm 
thick), consisting of watery lacrimal secretion provided by the numerous accessory 
lacrimal glands, most of which are situated in the upper conjunctival fornix. The 
innermost layer is the mucoin coat, which is secreted by conjunctival globet cells and 
glands of Manz. Mucin is involved in adhesion of the aqueous phase to the underlying 
corneal epithelium and acts as a wetting agent reducing the interfacial tension 
between corneal epithelium and tears (Saettone et al, 1999).  
The water-soluble elements of the tears are electrolytes, proteins and 
peptides such as albumin, lysozyme, lactoferrin, cytokines, growth factors etc (Lemp, 
2008).  
The tear film in the eye is constantly replenished and this process is 
connected to the blinking, which sweeps the excess fluid by the nasolacrimal duct. 
The lacrimal fluid in humans has a volume of 7 µL with pH 7.4 (Shahwal, 2011).  
 
 b. The Cornea. The cornea is an avascular, transparent structure composed 
of five layers with a total thickness of 300 – 500 µm. These layers include: epithelium, 
Bowman’s membrane, stroma, Descement’s membrane, and endothelium.  
The epithelium plays a critical role in the maintenance of a barrier against 
tearborne agents and in a balanced stromal hydration. It is composed of five to seven 
cell layers, with a total thickness of 35-50 µm. The cells at the base are columnar but, 
as they are squeezed forwards by new cells, they become flatter identifying three 
groups of cells: basal cells, an intermediate zone of 2-3 layers of polygonal cells (wing 
shaped) and squamous cells. The permeability of the intact corneal epithelium is low, 
suggesting that tight junctions exist between the cells of the outer layer. The outer 
layer of the surface cells possess microvilli on their anterior surface may be to anchor 
the precorneal tear film. The cells of the basal layer show extensive lateral 
interdigitation of plasma membranes and are, therefore, relatively permeable. 
Immediately adjacent to the epithelium there is a less ordered region of the stroma, 
the Bowman’s membrane followed by stroma, a hydrated (75-78% water) matrix of 
collagen fibrils and glycosaminoglycans (GAGs), which constitutes 90% of the corneal 
thickness. As structure purely hydrophilic, the stroma can act as barrier for very 
lipophilic substances. This arrangement is followed by Descement’s membrane and 
corneal endothelium. Descement’s membrane forms the basement membrane for the 
corneal endothelium. Corneal endothelium is a monolayer of polygonal cells, most of 
which are hexagonal in shape with about 20 µm diameter and 4-6 µm thickness. 
These cells play a key role in maintaining corneal transparency through their 
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transport, synthetic, and secretory functions (Sunkara and Kompella, 2003). The 
endothelium is in contact with aqueous humor of anterior chamber, and it is crossed 
by a passive flux of water towards the stroma while an active pump mechanism 
generates a flux in the opposite direction controlling corneal turgescence. 
 
 c. The Conjunctiva. The conjunctiva is a thin, transparent mucous membrane 
lining the inside of the eyelids and is continuous with cornea. The conjunctiva can be 
divided into three layers: (a) an outer epithelium, a permeability barrier, (b) substantia 
propria, containing nerves, lymphatics, and blood vessels, and (c) submucosa, which 
provides a loose attachment to the underlying sclera (Sunkara and Kompella, 2003). 
The conjunctiva, lining the lids, is vascular (palpebral conjunctiva) while on the globe 
is transparent (bulbar conjunctiva). The area between the lids and the globe is named 
conjuctival sac. 
 
d. The Sclera. Sclera is the white or opaque fribrous tissue that forms the 
external protective coat. It is composed, mainly, of collagen fibers, which have a 
haphazard arrangement that causes the opaque scleral effect (Boddu et al., 2013). 
Other elements present in the sclera are proteoglycans, elastin, proteins and cellular 
components and water. The main function of this tissue is to provide a protective 
layer for the internal components of the eye. 
 
 e. The Anterior Chamber and Aqueous Humor. The anterior chamber varies in 
depth and is bordered by cornea in the front and the pupil and iris diaphragm in the 
back. It is filled with aqueous humor produced by the ciliary epithelium in the posterior 
chamber. Aqueous humor is formed from blood plasma by mechanism of diffusion, 
ultrafiltration and active transport. The ciliary processes of the human eye produce 
aqueous humor at a rate of 2-3 µL/min. Before the aqueous humor reachs the 
anterior chamber, it flows throught the posterior chamber (Boddu et al., 2013). 
Furthermore, the aqueous humor production and the intraocular pressure are 
maintained by membrane transport processes (Sunkara and Kompella, 2003).   
 
 f. The Iris – Ciliary Body. The iris, ciliary body and choroid comprise the 
vascular uveal coat of the eye. The anterior iris is immersed in the aqueous humor, 
which enters the iris stroma through openings or crypts along its anterior surface. The 
iris receives its blood supply from the major arterial circle, which lies in the stroma of 
the ciliary body near the iris root. The ciliary body can be divided into the following 
regions: nonpigmented ciliary epithelium, pigmented ciliary epithelium, stroma, and 
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ciliary muscle. The main arterial blood supply to the ciliary body is through the long 
posterior and the anterior ciliary arteries (these capillaries are fenestrated and leaky) 
(Sunkara and Kompella, 2003).  
 
 g. The Lens - The lens is a transparent tissue, consisted of 65% water and the 
rest mainly by proteins. Anteriorly, the lens is in contact with the pupillary portion of 
the iris, and posteriorly it fits into a hollow depression of the anterior vitreous surface. 
The major components of the lens are capsule, epithelium, and lens fiber cells. The 
lens capsule is acellular, transparent, elastic, and acts as an unusually thick 
basement membrane that encloses the epithelium and lens fiber cells. Membrane 
transport proteins in the lens play an important role in cell volume regulation, nutrient 
supply, and lens transparency. All cells of the lens are interconnected by gap 
junctions (Sunkara and Kompella, 2003).   
 
 h. The Retina. The retina is mainly divided in two layers: neural retina (inner 
layer) and retinal pigment epithelium (RPE - outer layer). The neural retina comprises 
rods, cones, bipolar cells and ganglionic cells, which are involved in the conversion 
system of the light into electrical impulses that provides for the normal vision. RPE is 
a non-visual portion located between the neural section of the retina and choroid and 
consists of a layer of melanin–containing epithelial cells. Melanin helps in absorption 
of stray light rays entering the eyeball and prevents the reflection of scattering of light. 
The RPE forms a blood-retinal barrier through tight junctions that enable the 
neighboring cells to connect each other. These cells regulate the trans-epithelial 
transport of various molecules through apical tight junctions, which retard the diffusion 
through the paracellular spaces. The numerous microvilli on the neural retinal section 
help the absorption of various nutrients and thereby maintain the viability of the neural 
retina. RPE expresses certain efflux pumps, which block the entry of xenobiotics from 
the extravascular space of the retina (Boddu et al., 2013).  
 
 i. Vitreous humor. The vitreous humor consists in a viscous gel-like structure 
and represents the 80% of the total volume of the eye. This fluid fills up the space 
between the lens and the retina. Vitreous humor is composed by water (99%), 
hyaluronic acid, hyalocytes, inorganic salts, sugar, ascorbic acid and a network of 
collagen fibris. The network of non-branching collagen fibers with hyaluronic acid 
imparts viscosity to the vitreous humor (Boddu et al., 2013). While the aqueous 
humor is continuously replenished, vitreous humor has a lower turn over. It serves as 
a mechanical buffer for the surrounding tissues, exerts an important role in the 
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transmission of the light to the retina, and is involved in the maintenance of the 
intraocular pressure (Gajraj, 2012).   
 
 
2.The Ophthalmic Therapy 
 
Topical therapy is the most commonly used for treatment of diseases of the anterior 
segment of the eye such as ocular surface diseases (conjunctivitis, dry eye, keratitis, 
etc.), glaucoma and anterior uveitis.  These dosage forms like eye drops and 
suspensions are convenient and easy to instil but suffer from inherent drawbacks that 
lead to an ocular low bioavailability of drug due to, for example, the tear turnover, 
poor corneal permeability, nasolacrimal drainage, systemic absorption connected to 
side effects. To overcoming some of these problems and obtain an effective therapy, 
we can consider drug delivery systems, with a sustained drug release, both to prolong 
therapeutic activity and interact better with the ocular barriers or to reach specifically 
the drug’s site of action.  
However, topical therapies are limited for treating disorders of posterior segment due 
to the greater diffusional distance as well as anatomical and physiological barriers in 
the eye. In this case intravitreal drug injections have been explored for delivering 
drugs to target tissues in the eye at therapeutic concentrations. 
 
 
2.1 The Topical Ocular Administration 
 
 
Figure 2 - Model Showing precorneal and intraocular events following topical ocular 
administration of a drug. 
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The formulation intended to administer to the eye surface may be required either to 
act at the precorneal area or to penetrate through the ocular structures to act into the 
interior of the eyeball. First of all there are some anatomical and physiological 
constrains to take into account when we use a topical administration such as cul-de-
sac limited volume, the solution drainage, lacrimation, tear turnover, drug spillage for 
blinking, conjunctival-scleral absorption, enzymatic metabolism, and protein binding.  
 The ocular bioavailability remarkably depends on a suitable contact time with 
the cornea. Instilled solution drainage away from the precorneal area (within 5 
minutes after instillation in humans) has been shown to be the most significant factor 
reducing the permanence of drug in this area. The natural tendency of the cul-de-sac 
is to reduce its fluid volume to 7-10 µL because of the blinking. A typical ophthalmic 
dropper delivers 30 µL, but due to the aforementioned reason, most of the active is 
rapidly lost through nasolacrimal drainage immediately after the following 
administration. This drainage mechanism may then cause the drug to be systemically 
absorbed across the nasal mucosa or the gastrointestinal tract leading to important 
side effects. The tear turnover acts to remove drug solution from the conjunctival cul-
de-sac. Normal human tear turnover is approximately 16% per minute. Moreover, 
absorbed drug may set off the eye through the canal of Schlemm or via absorption 
through the ciliary body of suprachoroid into the episcleral space. In addition, even if 
the drop’s proteinaceus content (albumin, globulins, lysozyme) is very low (about 
0.7%), the continuous tear turnover produces new proteins  most of which can bind 
the drug molecules. Enzymatic metabolism may contribute for further loss, which can 
occur in the precorneal space and/or in the cornea. 
 The lacrimation (tear production), wihich leads to a diluition of the pharmaceutical 
form, also influences the ocular drug absorption. It can be induced by many factors 
such as the type and amount of drug, pH and tonicity of the dosage form, use of 
adjuvants.  
   All these factors may influence the ocular drug bioavailability that has been 
estimated to be 1-2% (or less) of the instilled dose (Macha et al., 2003).   
 Another important factor is the absorption of the drug into the conjunctiva and 
sclera, the so-called conjunctival/scleral pathway. Drug loss through this route of 
absorption may be significant. Conjunctival-scleral pathway is fairly permeable to 
hydrophilic and large molecule and may serve as a route of absortion for some larger 
molecules such as proteins and peptides (Urtti, 2006).  
 The mechanism of permeation of the drug through ocular tissues to arrive into 
internal structure of the eye is the passive diffusion governed by the Fick’s fist law 
shown above:  
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J  =  -­‐  D    !"!"    
where J is the flux rate through the membrane; D is the diffusion coefficient that 
depends on physico-chemical properties of the drug such as molecular size; dC/dx  is 
the concentration gradient, i.e., the ratio between the difference of concentration to 
the two sides of the barrier and the thickness of  the barrier. Another parameter that 
influences the flux of the drug through the ocular tissue is the partition coefficient (K), 
which indicates the affinity of the drug for the lipophilic or hydrophilic compartments. 
Equilibrium between the two characteristics (lipophilic or hydrophilic) is essential to 
promote the transocular permeation. It is possible to calculate partition coefficient 
value determining octanol/water partition coefficient. 
 If the topically administered drug must reach the anterior chamber of the eye, it 
has to pass through the corneal layers. Corneal epithelium, the first barrier, can be 
crossed though two pathways: transcellular (through the cells) and paracellular 
(between the cells) pathway (Fig. 3). Lipophilic molecules and molecules with 
specialized transport processes prefer the transcellular route, whereas hydrophilic 
molecules lacking membrane transport processes prefer the paracellular route 
(Shahwal et al, 2011).  
 The mechanism of transcellular transport includes simple diffusion, facilitated 
diffusion, active transport, and endocytosis. For the most of the available drug 
molecules, no such transporters or receptors exist, and these drugs are transported 
by passive diffusion through the apical membrane and across the basolateral 
membrane to move across the cell. During the transcellular movement, the solute 
must interact with some components of the cell membrane.  Physiochemical 
properties of the drugs that may influence drug penetration via the transcellular 
pathway, purely lipophilic, include: (1) the lipophilicity of the drug, reflected by its 
octanol-water partition coefficient; (2) its pKa (dissociation constant), which 
determines the amount of absorbed drug depending on its ionized or unionized form 
at a given pH; (3) molecular size.  
 Transport through the paracellular pathway is passive and only limited by the 
size and charge of the intercellular spaces. It is an aqueous route involving the 
diffusion of the solute between adjacent epithelial cells/endothelial cells restricted by 
the presence of the tight junctions or zonula occludens (ZO) (Sunkara and Kompella, 
2003).  
 For most drugs, the multicellular layered corneal epithelium presents the greatest 
barrier to penetration while stroma and endothelium offer little resistance. Indeed, for 
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too much lipophilic drugs, the corneal stroma represents a rate-limiting barrier to 
access the inner eye and in this case it may act as a reservoir from which the drug 
will be slowly delivered to the aqueous humor. Finally, the moderate lipophilic corneal 
endothelium does not offer significant resistance to drug absorption (Ye et al., 2013). 
In fact, the drug should be both oil and water soluble to across the corneal epithelium 
(lipid barrier) then the aqueous humor (Shahwal et al, 2011).  
 In addition to the classical corneal pathway, there is a competing and parallel 
route of absorption via the conjunctiva and sclera, the so-called conjunctival/scleral 
pathway; comparing the corneal route with this absorption pathway, it results that the 
second route is a minor absorption pathway, even tough for some compounds its 
contribution is rather significant. 
 Ahmed and Patton (1985, 1987) investigated corneal versus noncorneal 
penetration of topically applied drugs in the eye. They demonstrated that noncorneal 
absorption could contribute significantly to intraocular penetration. Drugs can bypass 
the anterior chamber and distribute directly to the uvea and vitreous. For low corneal 
affinity drugs such as inulin, this absorption route may be particularly important. In 
another study, Ahmed et al. (1987) evaluated in vitro the barrier properties of the 
conjunctiva, sclera, and cornea studying the diffusion characteristics of various β-
blockers. Permeability through the sclera of these compounds was higher than 
through the cornea related to their physicochemical properties. The results suggested 
that the pathway of absorption might be in part influenced by lipophilicity and that 
hydrophilic compounds seem to prefer the conjunctival/scleral route. Schoenwald et 
al. (1997) verified that a compound with a remarkable lipophilicity as rhodamine B did 
not pass through conjunctival/scleral barrier.	  	  	  	  
	  
Figure 3 - The cornea. Cellular organizayion of various transport limiting layers. 
  
 Introduction 
	   	   	   	   	  10	  
2.2 Intravitreal, Periocular and Systemic Administrations 
 
a. Intravitreal Administration. Intravitreal injection is the most direct approach for 
delivering drug to the vitreous humor and retina; however, this method of 
administration has been associated with serious side effects, such as 
endophthalmitis, cataracts, hemorrhage, and retinal detachment. In addition, multiple 
injections are usually required, further increasing the risk. Nevertheless, intravitreal 
injection continues to be the mode of choice for treatment of acute intraocular 
therapy.  
The kinetic behaviour of intravitreally delivered drugs is influenced by the normal 
vitreous physiology. Mechanisms that may influence movements of molecules within 
the vitreous include diffusion, hydrostatic pressure, osmotic pressure, convective flow, 
and active transport. For small and moderately sized molecule diffusion is the 
predominant mechanism of transvitreal movement; for this kinds of molecules, the 
diffusion within the vitreous is generally unimpeded and similar to that observed in 
water or saline (Chastain, 2003).  
 
b. Periocular Administration. Drugs usually do not reach therapeutically relevant 
levels of the active agent in the posterior segment via topical route. If significant 
concentrations are achieved at the back of the eye, they are usually the results of the 
redistribution from the systemic circulation, not local delivery. Consequently, to treat 
diseases of the posterior segment, drug must typically be administered intravitreally, 
periocularly, or systemically. Periocular drug administration, using subconjunctival, 
sub-Tenon’s, or retrobulbar injection, is another and, in many cases, preferred, route 
for delivering drugs to the posterior segment.  
 Subconjunctival injection offers the advantage of local drug delivery without 
the invasiveness of intravitreal injection. This route also allows for the use of drug 
depots to prolong the duration of drug therapy and avoids much of the toxicity 
encountered with systemic administration. Drug concentrations in the eye are typically 
substantially higher following subconjunctival versus systemic administration, while 
systemic exposure is greatly reduced with subconjunctival dosing.  
 Maurice and Mishima (1984) point to direct penetration to deeper tissues as 
the main pathway of entry into the anterior chamber. The drug must saturate the 
sclera to enable the absorption by this route. This condition is followed by diffusion by 
various possible routes: laterally into the corneal stroma and across the endothelium, 
across trabecular mesh-work, through the iris stroma and across its anterior surface, 
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into the ciliary body stroma and into newly generated aqueous humor, and into the 
vitreous body via the pars plana and across its anterior hyaloid membrane. In addition 
to these pathways, depending on the injection volume, regurgitation out the dose site 
with subsequent spillage onto the cornea can lead to direct transcorneal absorption.  
 Sub-Tenon’s injection involves delivery of drug, usually as a depot, between 
the sub-Tenon’s capsule and sclera or episclera. This route of administration has the 
advantage of placing drug in very closely proximity to the sclera. Drug can 
subsequently diffuse through the sclera, which is quite permeable to a wide range of 
molecular weight compounds (Chastain, 2003).  
 
c. Systemic Administration. This kind of administration is generally not preferred 
because of the several side effects. However, for drug delivery to the posterior 
segment or vitreous body, systemic administration could be the best choice 
depending to the drug’s ability to penetrate the blood-retinal barrier or the blood-
vitreous barrier and its systemic toxicity profile (Chastain, 2003).  
 
 
3. Ocular Drug Delivery Systems 
 
The pharmaceutical forms more commonly used in ophthalmic field can be classified 
on the basis of the physical form in: 
 
• Liquid dosage forms: solutions and suspensions; 
• Semisolid dosage forms: ophthalmic ointments and gels; 
• Solid dosage forms: ocular inserts.   
 
Although many techniques of instilling drugs to the eye have been 
experimented with, the use of eye drops remains the main method of administration 
for the topical ocular route. The two major physical forms of eye drops are aqueous 
solutions and suspensions. A homogeneous solution offers the potential of greater 
assurance, of uniformity of dosage and bioavailability and simplifies large-scale 
manufacture. Furthermore, the solution is more easily administrable with an excellent 
patient compliance even if it has, as fundamental drawback, the low bioavailability 
due mainly to the rapid and extensive precorneal loss, the high absorption via the 
conjunctiva and the nasolacrimal duct leading to systemic side effects. When the drug 
is not sufficiently soluble in hydrophilic vehicle a suspension can be formulated. A 
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suspension may also be desired to improve stability, bioavailability or efficacy. Most 
of ophthalmic suspensions are composed of the steroid antiiflammatory agents (such 
as prednisolone acetate, dexamethasone). The critical element of these formulations 
is the size of particles. Micronized particles (size <10 µm) are accepted in ophthalmic 
field to not cause irritation of sensitive ocular tissues and to help ensure that a 
uniform dosage is delivered to the eye. In any case there are a lot of constraints 
connected to preparation and administration of a stable suspension, i.e., they need to 
be adequately shaken before use to ensure the correct dosing and reach a moderate 
increase in bioavailability; and also the suspensions are expensive in terms of 
production costs. 
To increase the ocular contact time and subsequently improve ocular 
bioavailability of the drug, high molecular weigh polymers can be added to the 
ophthalmic solutions and suspensions raising their viscosity. The most commonly 
used hydrophilic polymers in ocular field are polyvinyl alcohol (PVA) and polyvinyl 
pyrrolidone (PVP), and cellulose derivatives such as hydroxypropyl methylcellulose 
(HPMC), methylcellulose (MC) and polyacrylic acids (carbopols) (Shahwal et al., 
2011).  
There are many examples on the market of eyedrops containing rheological 
modifiers such as Fluaton®, containing PVA, Flarex® containing HEC, Flumetol® 
containing a mixture of PVA and HPMC, Retaine® HPMCTM lubricant eye drops 
containing HPMC. 
There is a direct relationship between viscosity and bioavailability up to a 
plateau after which further increase in viscosity produces only slight or no increase in 
therapeutic effect. Many research works have demonstrated this correlation and led 
to the conclusion that ophthalmic liquid formulations should have viscosity in the 
range of 25 to 50 cP for a greatest permanence in the precorneal area. The addition 
of a 0.5% PVA solution to eye drops increases the viscosity to about 3 cP (water 
viscosity= 1 cP) and decreases the drainage rate of topically applied eye drops as 
compared with aqueous solution. The drainage rate decreases by a factor of 2-3 at 
viscosities up to 7.7 cP and further increase in viscosity from 7.7 to 75.8 cP is also 
associated with a decrease by a factor of 2-3. The rate of drainage decreases with 
additional PVA up to a maximum of 3%, after which there is no longer any advantage 
(Kebler et al., 1991). 
 Redkar et al. (2000) evaluated the influence of the viscosity of new possible 
commercial artificial tears on increasing the permanence time of the formulation in the 
precorneal area and on producing a stable tear film. MOISOL® eye drops (0.3% 
HPMC) was used as reference. As viscosity-imparting agents, HPMC and Dextran 70 
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were used individually or in combination. An aqueous formulation containing dextran 
70 (0.1% w/v) and HPMC (0.7% w/v) appeared the best to maintain for a long time a 
stable tear film. The experimental formulation with a viscosity of 25.49 cP produced a 
longer permanence in the precorneal area of the eye drops (2h) than the reference 
MOISOL which has a viscosity of 42.30cP and a precorneal permanence time of 1,5 
h. This seems to confirm that high viscosity is not necessarily correlated with a high 
bioavailability.  
In addition to their thickening effect, many aforementioned polymers possess 
mucoadhesive properties, i.e. ability to establish adhesive, non covalent bonds with 
mucin layers coating corneal-conjunctival epithelium, giving ophthalmic drug delivery 
systems longer times of contact with the absorbing tissues. For an efficient 
mucoadhesive activity the polymers need to have one or more of the following 
features: strong hydrogen binding group, strong anionic charge, high molecular 
weight, sufficient chain flexibility, surface energy properties favoring spreading onto 
the mucus. The combination of mucoadhesion and viscosity is a target for an optimal 
activity (Saettone et al, 1999). 
The principle semisolid dosage form used in ophthalmology is anhydrous 
ointment with a petrolatum base or a mixture of petrolatum and lanolin derivatives. 
Ophthalmic ointments containing antibiotics are used quite frequently following 
operative procedures. The reduction of dilution of medication via the tear film, 
resistance to nasolacrimal drainage, and increased precorneal contact time lead to a 
remarkable increase of bioavailability, whereas the blurred vision, and the discomfort 
by the patient are disadvantages that limit its use to a night treatment. 
An aqueous semisolid gel base has been developed to provide significantly 
longer residence time into the cul de sac. The gel consists of a high molecular weight, 
crosslinked, polymer to provide high viscosity and optimum rheological properties for 
prolonged ocular retention.  Only a relatively low concentration of polymer is required, 
so that the gel base is more than 95% water. 
In-situ gelling systems are viscous polymer-based liquids that exhibit sol-to-gel 
phase transition on the ocular surface due to change of specific physic-chemical 
parameter (electrolyte composition, the change in temperature, pH). This kind of 
formulation has many advantages, i.e., an easy instillation, a prolonged residence 
time of the formulation on the surface of the eye (due to gelling), an easy, 
reproducible, accurate administration of a dose compared to the application of 
performed gels.  
The ophthalmic inserts are solid devices designed to deliver the drug in the 
conjunctival cul-de-sac or in the posterior segment of the eye. The main objective of 
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ophthalmic inserts is to increase the contact time between the formulation and the 
conjunctival tissue to ensure a sustained release suited for topical or systemic 
treatment, resulting in an improved bioavailability. 
 
 
3.1 Ophthalmic Inserts and Implants 
 
Ocular inserts are defined as sterile preparations, with a thin, multilayered, drug-
impregnated, solid or semisolid consistency devices placed into the cul-de-sac or 
conjunctival sac or introduced into the interior structure of the eye during surgery 
(implants), and whose size and shape are especially designed for ophthalmic 
application. Ocular inserts are sustained-release drug delivery systems (Lee et al., 
2011). In general matrix implants are typically used to treat acute-onset diseases that 
require a loading dose followed by tapering doses of the drug during a 1-day to 6-
month time period. 
The main advantages to use ocular inserts are listed below: 
• Increasing the contact time and thus improving bioavailability; 
• Release of drugs at a slow, constant rate; 
• Reduction of systemic absorption, lowering consequently side effects; 
• Minor number of administrations and thus better patient compliance; 
• Possibility of targeting internal ocular tissues through non-corneal 
(conjunctival scleral) routes. 
One of the major disadvantages of ocular inserts resides in their ‘solidity’, which 
is felt by the patients (often oversensitive) as an extraneous body in the eye. This 
may constitute a difficult physical and psychological barrier for patient compliance. 
Furthermore, inserts can cause an interference with vision, causing some problems 
related to them placement (and removal, for insoluble types). 
Depending on the type of polymeric material used to prepare the inserts, they 
can be classified in two main classes: a) nonbiodegradable and b) biodegradable 
ocular delivery systems. 	  
a. Nonbiodegradable Ocular Delivery Systems. Ocular inserts composed by 
nonbiodegradable polymers are insoluble and therefore they have to be removed 
from the eye at the end of the short treatment.  
The ophthalmic nonbiodegradable systems can be characterized as reservoir-
type and implant-type. In the former type a drug core is slowly released across a 
nonbiodegradable semipermeable polymer or is released from a nonbiodegradable 
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polymer through the opening of a fixed area; in the latter type a nonbiodegradable 
free-floating pellet is injected intravitreally or a nonbiodegradable plug is anchored to 
the sclera.  
Reservoir type is generally consisting of a combination of polyvinyl alcohol 
(PVA) and ethylene vinyl acetate (EVA). PVA, a permeable nonbiodegradable 
polymer, is used as the main structural element, and EVA, a nonbiodegradable 
polymer that is lipophilic and relatively impermeable to hydrophilic drugs, is used for 
the device’s semi-permeable membrane. Indeed, the release of the drug from the 
reservoir-type system occurs by the diffusion of the water through the outer EVA 
coating, which partially dissolves the enclosed drug and forms a saturated drug 
solution that diffuses into the surrounding tissue depending on the concentration 
gradient. As long as the drug remains within the core, a near zero-order drug release 
kinetic with a relatively constant release rates is obtained when the steady state 
condition is achieved. The duration of drug release is mainly limited by the rate of 
drug dissolution within the reservoir.  
On the other hand, the nonbiodegradable implants, devices to introduce in the 
internal structures of the eye, have a lot of drawbacks. For example large incisions 
and sutures or other form of anchoring can be necessary; the implantation and their 
removal can cause serious side effects such as retinal detachment, vitreous 
hemorrhage, and cataract formation.  
Examples of nonbiodegradable devices reservoir-type to apply in the precorneal 
area available on the market are Mydriasert® and Ocusert®.  
Mydriasert® is an oblong (4.3 mm x 2.3 mm), nonbiodegradable cylinder 
(reservoir) with rounded forms containing tropicamide and phenylephrine 
hydrochloride with ammonium methacrylate copolymer (Type A), polyacrylate 
dispersion (30%), and ethyl cellulose, as excipients. The reservoir is surrounded by a 
dyalisis membrane. When the system is introduced in the conjunctival sac, the tears 
enter into the device by osmotic effect and the active components are released 
through the membrane.  It is mainly used to induce pre-operative mydriasis, allowing 
the mydriasis to be obtained quickly and to be maintained during surgery. It has to be 
removed from the conjunctival sac within two hours.  
 
                                                    
Figure 4 – Mydriasert® 
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Instead, Ocusert®  (Fig. 5.a-b) is a nonbiodegradable conjunctival insert that 
provides sustained delivery (zero-order kinetics) of pilocarpine hydrochloride for the 
treatment of glaucoma. It consists of pilocarpine and alginic acid contained within a 
reservoir enclosed by two release-controlling membranes made of EVA copolymer 
surrounded by a ring to aid in positioning and placement (Fig. 5.a). While this product 
represented an innovation in ophthalmic drug delivery technology, its use was limited 
by complications associated with device insertion (Lee et al., 2011).  
 
 
                     Figure 5.a - Ocusert® structure.                      Figure 5.b - Ocusert ® placement in the eye. 
 
Some examples of nonbiodegradable intravitreal implants are Retrisert® (Bausch 
and Lomb, Inc. Rochester, NY/pSivida Ltd.) and Iluvien® (formerly Medidur; Alimera 
Sciences, Inc., Alpharetta, GA, USA) containing fluocinolone acetonide (FA), 
Vitrasert® (Bausch and Lomb, Inc., Rochester, NY, USA) containing gancyclovir 
(GAC) and I-vation ™ (SurModics, Inc., Eden Prairie, MN) based on triamcinolone 
acetonide (TA). 
Used for the treatment of chronic non-infectious uveitis affecting the posterior 
segment of the eye, Retrisert® is a disc-shaped intravitreal implant consisting of a 
matrix of fluocinolone acetonide coated with silicone and PVA attached to a 5.5-mm 
silicone suture tab. It is surgically inserted in the vitreous at the pars plana near the 
ciliary processes. The device has an initial drug delivery rate of 0.6 mg/day and 
reaches a steady-state delivery rate of 0.3–0.4 mg/day over roughly 30 months. 
Furthermore, Retrisert® received fast-track approval status and orphan drug 
designation from the U.S. Food and Drug Administration (FDA) for the treatment of 
chronic noninfectious uveitis of the posterior segment and diabetic macular edema 
(DME).  The implant showed efficacy versus diabetic ocular edema, but was linked to 
the cataract onset and intraocular pressure increase after 3 years treatment (phase 3 
clinical trial), indicating that, this implant is not suitable for long-term treatment (Lee et 
al., 2011).  
Instead, the IluvienTM intravitreal insert (Fig. 6), is a tiny cylindrical polyimide 
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tube, 3.5mm in length and 0.37mm in diameter, that contains 180 µg of FA. It has a 
reservoir fitted with end cap of PVA or silicone (in the 0.2mg/day dose version) that 
regulates the rate of drug release and provides nearly zero-order kinetics, with a 
slightly higher initial release rate that stabilizes over the long term. It is inserted using 
a proprietary 25-gauge injector system into the inferior vitreous to maximize drug 
exposure to the retina and minimize exposure to the anterior chamber. This implant 
exists in two different doses: 0.2 mg/day and 0.5 mg/day, which the lasting time is 
24–30 months and 18–24 months respectively. By combining FA and a delivery 
device that provides for a unique long term, low dose delivery of FA to the back of the 
eye, it is believed that IluvienTM has the potential to improve vision of those suffering 
from diabetic macular edema, while reducing common side effects of corticosteroids 
(Lee et al., 2011).  
 
 
Figure 6 - IluvienTM: Comparison to grain of rice and on adult’s finger. 
 
Vitrasert® (Fig. 7) is a nonbiodegradable polymeric intravitreal ganciclovir 
implant developed for the treatment of cytomegalovirus retinitis. Ganciclovir (GAC) is 
encapsulated within a reservoir, encased by a PVA/EVA membrane, and diffuses out 
according to zero-order release kinetics when fluids enter the device and create a 
saturated solution.  The device provides GAC sustained release for 5–8 months and 
achieves higher intraocular drug concentrations as compared with systemic 
administration. It is ideal for cytomegalovirus retinitis lesions that pose an immediate 
risk to vision (Lee et al., 2011).  
 
 
Figure 7 - Vitrasert® 
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I-vationTM (Fig. 8) is a nonbiodegradable intravitreal implant consisting of a 
titanium helical coil coated with TA (925 µg) and the nonbiodegradable polymers 
poly(methyl methacrylate) and EVA. I-vation™ has a sharpened tip, used to do the 
incision for implantation, and its helical shape maximizes the surface area for drug 
coating and enables secure anchoring to the pars plana/sclera. It is predicted that this 
implant will have an in vivo sustained delivery of at least 2 years. I-vationTM had been 
under investigation for the treatment of DME, but early trials evaluating the device 
reported the incidence of intraocular pressure elevation, conjunctival hemorrhage 
lenticular opacities, and endophthalmitis (Lee et al., 2011). 
 
 
Figure 8 - I-vationTM 
 
b. Biodegradable Ocular Delivery Systems The peculiarity of biodegradable 
ODS is the presence of biodegradable polymers. Biodegradable polymer-based drug 
delivery systems show considerable promise for the treatment of ocular diseases and 
offer a potential solution to many of the limitations of conventional methods (systemic, 
oral and topical) for administration of ophthalmic drugs. Biodegradable polymer-based 
drug delivery can be used to achieve prolonged therapeutic drug concentrations in 
ocular target tissues with a controlled release rate. 
The polymers used in biodegradable drug delivery systems have to be 
biocompatible and either leading to non-toxic metabolites or easily eliminated by 
endogenous metabolic pathways in the human body. An important characteristic for a 
biodegradable device is the mechanical strenght, i.e., it should be able to withstand to 
in vivo physical stress maintaining a structural integrity for a long enough period 
during the therapy. The drug release profile is depending on the choice of the polymer 
in particular to its biodegradation kinetics, physicochemical properties, and 
thermodynamic characteristics. The most used polymers for biodegradable inserts 
development are synthetic aliphatic polyesters of the poly-α-hydroxy acid family, 
which include poly (glycolic acid)(PGA), poly(lactic acid)(PLA), and the PGA/PLA 
copolymer poly(lactic-co-glycolic acid) (PLGA), poly( ε -caprolactone) (PCL), 
poly(glycolide-co-lactide-co-caprolactone) (PGLC), and others biomaterials such as 
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poly (ortho esters) (POE), polyanhydrides (PAH), polymethylidene malonate (PMM), 
polypropylene fumarate (PPF), and poly (N-vinyl pyrrolidone) (PVP). Among natural 
polymers, we can remember collagen, gelatin, chitosan, corn starch, amylo (high 
amylose starch). As shown in the Figure 9, the polymer chains gradually undergo a 
random scission that occurs more readly in center of the device. Once chains reach a 
threshold of reduced molecular weight, the shortened polymer chains become 
solubilized in the surrounding medium and are released from the device. This results 
in central hollowing of the implant with gradual mass loss of the implant. 
 
	  
Figure 9 - Biodegradable insert erosion. 
 
The Figure 10 illustrates what happens when a device undergoes to a bulk and a 
surface erosion process. In the former process (bulk erosion, that is shown in red) the 
dry implant shows porous structure prior the implantation and the drug molecules are 
interspersed in the pores and skeleton of the polymer (magnified view of Fig.10). After 
implantation, the implant is going towards a short burst phase of the drug (b-Fig. 10), 
during which the drug molecules diffusing out of the implant surface due to water 
penetration through the polymer pores present on its surface. Diffusion and random 
chain scission phase occurring immediately after burst phase. Consequently, the long 
polymer chains are split at random locations. At the same time, water molecules and 
drug molecules entering and exiting the implant from the core, respectively. The final 
phase consisting in the biodegradation and mass loss (d-f of Fig. 10) during which the 
polymer structure appears break down from internal cavitation and much of the drug 
molecules have already diffused out from the cavity. Structural changes and 
consequently implant shape alteration have occurred because of biodegradation 
process. Is clear that water molecules are still passing through the polymer and less 
drug is available for release. Towards the end of biodegradation, only the implant 
fragments remain.  
 The latter process (surface erosion, that is shown in blue) proceeds in the 
same way of the bulk process until burst phase (included). After this phase the 
surface erosion begins (i-Fig. 10), during which drug and polymer are both solubilized 
only on the surface of implant. The continuous surface erosion results in mass loss 
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from the surface of the device (j-l of Fig. 10). In this way, drug and polymer are 
released and solubilized from the surface of the implant, and its volume and surface 
are gradually reduced over time.  
 
Figure 10 - Drug-release mechanisms and biodegradation of matrix implants. 
 
An example of a biodegradable insert to applied in the precorneal area is 
Lacrisert®. It is a sterile, translucent, rod-shaped, water-soluble, biodegradable 
ophthalmic insert consisted of hydroxypropyl cellulose (HPC) to stabilize and thicken 
the precorneal tear film and prolong tear breakup time. It is indicated in moderate to 
severe dry eye syndrome. Lacrisert® side effects are typically mild and include blurred 
vision, ocular discomfort/irritation, eyelash matting/stickiness, photophobia, 
hypersensitivity, eyelid edema, and hyperemia (Lee et al., 2011). 
 Surodex (Allergan, Inc., Irvine, CA) is a rod-shaped biodegradable matrix  (1.0 
Å~ 0.5 mm) consisting of 60 µg of dexamethasone incorporated into the polymer 
matrix (poly(lactic-glycolic)-acid (PLGA) and  HPMC. After insertion into the anterior 
chamber, it produces sustained and controlled release of dexamethasone over 7 
days, achieving higher intraocular drug levels than conventional dexamethasone eye 
drops. It is used to control postoperative inflammation following cataract surgery. 
Instead Ozurdex™ (formerly Posudex, Allergan Inc., Irvine, CA), is designed to 
the application into the posterior segment of the eye.  It is a biodegradable implant 
consisting of 0.7 mg dexamethasone incorporated into a solid, rod-shaped PLGA 
copolymer (Novadur™, Allergan, Inc.) matrix. The implant is designed to release 
dexamethasone biphasically, with a peak doses for 2 months initially, followed by 
lower therapeutic doses for up to 6 months. Ozurdex received US FDA approval in 
June 2009 for the treatment of macular edema associated with retinal vein occlusion. 
During the clinical trials two main adverse events significantly and frequently occurred 
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in the treatment group: anterior chamber flare (5% for Ozudex vs. 0% for observation) 
and increased intraocular pressure (6% for Ozuderx and 0% for observation). Only 
2% of total patients of the trial group using Ozurdex and only 1 patient (1%) in the 
observation group had an intraocular pressure increase of 10 mmHg or more from 
baseline at day 90 (Lee et al., 2011). 
 
 
Figure 11 - Ozurdex™ implantation.  
 
 
 
Figure 12 - Ozurdex™ after three weeks implantation in the target site. 
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II. Experimental Section 
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4. Aim 
   
The main goal of this thesis is the development of an ophthalmic biodegradable 
insert containing fluocinolone acetonide (FA), to apply in the posterior segment of the 
eye. Furthermore, this device should easily circumvent constrains that usually affect 
the administration of drugs in the posterior segment of the eye (repeated injection, 
systemic absorption of the drug, uncontrolled drug release, drug precorneal loss, 
etc.).  
The inserts under study were prepared by research group of Pharmaceutical 
Technology of the Department of Pharmaceutical Sciences - University of Milan (Prof. 
Gazzaniga) using the hot-melt extrusion technique. The matrices contained 3% FA 
and different polymeric materials.  
 In a previous study, insert made of hydroxypropyl cellulose (HPC-FA) was 
selected as the best with respect to a wide range of devices tested. Afterwards, new 
inserts containing amylo-maize starch N-400 (AMYLO), corn starch (CS) or corn 
starch with magnesium stearate (CS-MS) were prepared. All were added of FA 
(AMYLO-FA, CS-FA and CS-MS-FA, respectively). First of all, the behaviour of the 
new inserts in contact with isotonic buffer saline (PBS; 66.7mM, pH = 7.4) maintained 
at 37°C was analysed by visual examination: the swelling and the dissolution 
properties were monitored over time by using a digital microscope. On the basis of 
the results obtained by these experiments, AMYLO-FA appeared the most suitable to 
our goals.  
The physicochemical characteristics of the inserts above selected  (HPC-FA and 
AMYLO-FA) were determined by a) in vitro drug release analysis to determine the 
influence of the insert composition and the production technique on the profile of drug 
release and by b) differential scanning calorimetry (DSC) focused on the potential 
drug–polymer interaction and the structural changes that may occur during the hot-
melt extrusion process.  
The second part of this thesis aimed at tuning up cylindrical matrices by freeze-
drying for administration of vancomycin (VA) in the precorneal area to produce a 
sustained release of drug and consequently to reduce the number of applications. 
The matrices were subjected to the same tests above described (in vitro VA 
release analysis and DSC) to determine their physico-chemical properties. 
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5. Materials and Methods 
 
5.1 Materials 
 
The following products were used:  
! High amylose maize starch (AMYLO) (Amylo-maize starch N-400) (Roquette 
S.p.a, Italy)  
! Corn starch (CS), (Sigma Aldrich, Chemie GmbH, Germany)  
! Magnesium stearate (MS), (Sigma Aldrich, Chemie GmbH, Germany) 
! Hydroxypropyl cellulose (HPC,  KLUCEL®HF- PM 1150000) 
! Hydroxypropyl methylcellulose (HPMC, Methocel K4M premium EP, Colorcon, 
UK) 
! Fluocinolone Acetonide (FA), (Sigma Aldrich, Chemie GmbH, Germany) 
! Vancomycin Hydrochloride (VA) – European Pharmacopoeia (Sigma Aldrich,  
Chemie GmbH, Germany) 
! All other chemicals and solvents were of analytical grade. 
 
5.1.1 AMYLO 
 
AMYLO is a polymer composed by native starches that represent the 
carbohydrate fraction of the grain or tuber, obtained after the separation of the other 
components via a wet process extraction. They consist of starch granules that have 
not undergone any physical or chemical transformation. Depending on whether they 
are obtained from corn, wheat, potato or pea, native starches present different 
characteristics according to the size and structures of the starch granules, and 
depending on the ratio between amylose and amylopectin as summarized in Table 
5.1. In particular, in our study we compared AMYLO, a high amylose (60%) maize 
starch, with respect to corn starch (CS) containing only 25 % of amylose. 
 
 
Table 5.1 - Amylose and Amylopectin contents (%) of native starches. 
 (*) High amylose starch. 
 
Components Corn starch 
Wheat 
starch 
Potato 
starch 
Pea 
starch 
Amylo-maize 
starch N-400 
(*) 
Waxy 
maize 
starch 
Amylose 25 25 20 35 60 1 
Amylopectin 75 75 80 65 40 99 
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5.1.2 HPMC 
 
Hydroxypropyl methylcellulose (HPMC) is a semisynthetic, inert, viscoelastic 
polymer used as an excipient and controlled-delivery component in different 
medicaments to be administered for example orally, topically and ophthalmic; it is 
found in a variety of commercial products. It is a synthetic modification of the natural 
polymer, cellulose (Ghosal et al., 2011). 
 
                                       
 
 
5.2 Preparation of FA-loaded Inserts 
 
The inserts were prepared in the laboratory of Biopharmaceutics and 
Pharmaceutical Technology, Department of Pharmaceutical Sciences – University of 
Milan under the supervision of Prof. Gazzaniga.  
The hot-melt extrusion technique was performed. First, AMYLO was granulated 
in a mortar with water (20% by weight with respect to the dry polymer) and glycerol 
(20% by weight with respect to the dry polymer); next, fluocinolone  (3% by weight on 
the plasticized polymer) was added and the final mixture was extruded with no 
recycle through a twin-screw extruder (Haake MiniLab II, Thermo Scientific, USA) 
equipped with counter-rotating screws and a rectangular die (4x1 mm) at 100°C at 
110 rpm. The resulting products were 1.0 mm thick, 4.0 mm wide and 250.0 mm long 
from which, through the use of a scalpel, inserts of appropriate size (1.0 x 4.0 x 12 
mm) were obtained. The inserts, whose composition is shown in table 1, had a weight 
ranging between 0.033 g and 0.044 g. 
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5.3 Swelling and Dissolution Properties 
 
Each insert was immersed in 4 mL of isotonic, 66.7 mM, pH 7.4 phosphate 
buffer solution (PBS) added of 20 µL of 0.02 %w/w methylene blue solution obtaining 
dye final concentration of 0.004 %w/w. The medium was kept at 37°C.  
 At predetermined time intervals, an image of each insert was captured using a 
digital microscope (Dino-lite Pro, ANMO, Taiwan). Computer analysis of the images 
was done using Dino Capture 2.0 Software (ANMO, Taiwan) to determine the ability 
of dye solution to penetrate into the inserts, transparency and shape retention of the 
inserts. End point of the test was loss of form, swelling, and/or the presence of 
fracture lines. 
 
5.4 In Vitro FA Release Studies  
 
At the beginning, in vitro release studies were carried out using Gummer-type 
vertical diffusion cells. Each insert (HPC-FA and AMYLO-FA), exactly weighed (FA 
average content: 1.3 mg), was introduced in a metallic tiny net support and placed in 
the receiving chamber of the diffusion cell that was hermetically sealed to avoiding 
the evaporation phenomenon. The receiving chamber contained 5 ml of PBS that was 
continuously replaced with fresh fluid at flow rate of 0.4 ml/min by a peristaltic pump 
(Minipuls 3; Gilson, Villers-le-Bel, France). The system was thermostated at 37°C. At 
predetermined time intervals, the fluid was withdrawn for analysis. A first part of the 
experiments lasted 52 h. Subsequently the release test was continued for 192 h only 
for AMYLO-FA insert.	  Both experiments were repeated 3 fold. 
The release rate of FA from AMYLO-FA inserts was also determined using 
another experimental method by referring to Mruthyunjaya et al., 2006. Briefly, the 
inserts (FA average content: 1.3 mg) was put in contact with 1 mL of PBS in glass 
narrow vials maintained at 37 °C. The entire solution was withdrawn for analysis at 24 
or 48-hours time intervals and replaced with fresh PBS. The tests lasted 25 days. In 
all cases the amount of released drug was determined by HPLC. 
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5.5 FA Analysis Method 
 
The quantitative determination of FA in receiving phase was carried out by 
HPLC. The apparatus consisted of Shimadzu LC-20AT system with an UV-SPD-6AV 
detector and the injection valve was a Rheodyne with a capacity of 20 µL. A Kinetex 
Phenomenex® C18 100 A (5 µm; 150 x 4.6 mm) column was employed. The mobile 
phase consisted of a mixture of methanol: MilliQ-water (55:45). The detection 
wavelength was 238 nm, the flux was 1.0 mL/min, and the retention time was 8.35 
min at the average pressure of 160 kgf/cm2.  
 The amount of FA in the samples was determined by comparison with 
appropriate standard curve. It was determined with known FA-concentration solutions 
in the range of 0.004 µg/mL - 5.100 µg/mL. For the determination of the calibration 
curve the following procedure has been made: FA was solubilized in methanol and 
later progressive dilutions were made adding PBS  (Chmielewska et al., 2006). 
The amount of FA in the samples was determined by comparison with 
appropriate calibration curve that was linear  (r2= 0.983) in the range of 0.004 µg/mL - 
5.10 µg/mL. 
 
5.6 DSC Analysis  
 
The possible drug-polymer interaction was studied by the DSC performed for 
fluocinolone acetonide (FA powder), pure polymer (AMYLO powder), physical mixture 
between drug and polymers (AMYLO-FA physical mixture in the ratio of 97:3; 70:30 
and 50:50), unmedicated ocular inserts (AMYLO extruded), and medicated ocular 
inserts (AMYLO-FA extruded). 
DSC analysis was performed using a Perkin Elmer differential scanning calorimeter 
(DSC 6, PerkinElmer, Italy). The apparatus was calibrated with purified zinc (99.9%). 
Samples (3–4 mg) were placed in flat-bottomed aluminum pan and heated at a 
constant rate of 20°C/min. Nitrogen, at the rate of 20 ml/min, was used as a purge 
gas during the role analysis. The specimens were heated from 30°C to 350°C. 
The thermogravimetric curves were recorded with Pyris Instrument Managing 
Software, (Version 11, Perkin Elmer, Italy). 
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5.7 Preparation of VA-loaded Inserts  
 
Inserts were prepared by employing freeze-drying technique. The matrices were 
prepared through the following procedure: first of all, HPMC was hydrated in MilliQ-
water (1 %w/w) at room temperature for 12 h; 10 mg of VA was dissolved in 240 
microliters of the polymeric dispersion to prepare five inserts.  50 µL of the final 
mixture were introduced in a silicon cylindrical plate with 3 mm diameter and were 
lyophilized using the following freeze drying process parameters: 
 
• The freezing phase was carried out at - 40°C for 120 min, followed by an 
extrafreeze time at – 36°C for 10 min at a pressure of 400 Torr.  
• The primary drying was carried out in four steps: 
" Step 1: - 25°C for 360 min at 100 mTorr (rate: 1.8°C/h) 
" Step 2: - 10°C for 240 min at 100 mTorr rate: 3.75°C/h) 
" Step 3: + 5°C for 420 min at 100 mTorr (rate: 2.1°C/h) 
" Step 4: + 25°C for 240 min at 100 mTorr 
• The secondary drying was carried out at + 27°C for 120 min at 50 mTorr 
Each freeze-dried insert contained 0.5 mg of HPMC and 2 mg of drug. 
 
 
5.8 In Vitro VA Release Studies  
 
In vitro release of VA from the lyophylized matrices (HPMC-VA) was 
investigated using Gummer-type diffusion cells with effective diffusional area of 1.477 
cm2. A previously hydrate cellulose ester membrane (Spectra/Por® 1 Dialysis 
Membrane, MWCO 6-8 kDa) was placed between the receiving and the donor 
compartments. 5 ml of PBS, kept at 32°C and stirred at 400 rpm, were used as 
receptor medium. The dialysis membrane was able to retain polymeric materials but 
to pass drug into the release medium. The matrices (donor phase) were put in contact 
with the membrane, moistened with 10 or 50 microliters of MilliQ water and the donor 
section was hermetically sealed. At predetermined time intervals, samples of the 
receiving phase were withdrawn for the analysis and replaced with an equal volume 
of fresh buffer. The amount of released VA was determined by HPLC. Each test was 
replicated at least 2 times. 
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5.9 VA Analysis Method 
 
 The quantitative determination of VA in receiving phase was carried out by 
HPLC. The apparatus consisted of a Shimadzu LC-20AD system with an UV SPD-
10A detector equipped of autosampler SIL-10AD VP and a computer integrating 
system. A Kinetex Phenomenex® C18 100 A (5 µm; 150 x 4.6 mm) column was 
employed. The mobile phase consisted of a mixture of phosphate buffer: acetonitrile 
(90:10). The buffer solution consisted of monohydrated sodium dihydrogen phosphate 
(20 mM) and sodium hydrogen phosphate (30 mM) mixed in a ratio of 80:20. The 
detection wavelength, the flux and the retention time were 210 nm, 1.0 mL/min and 
4.74 min, respectively, at the average pressure of 130 kgf/cm2.  
 The amount of VA in the samples was determined by comparison with 
appropriate standard curve obtained by dissolving VA in MilliQ water and then diluting 
the resulting aqueous solution with PBS. The calibration curve was linear (r2=0.998) 
over the concentration range studied (0.03504	  µg/mL – 4.56 µg/mL). 
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6. Discussion and Results  
 
The main goal of this thesis is the development of an ophthalmic biodegradable 
insert containing fluocinolone acetonide (FA), to apply in the posterior chamber of the 
eye. The inserts were prepared by research group of Pharmaceutical Technology of 
the Department of Pharmaceutical Sciences - University of Milan (Prof. Gazzaniga) 
by the hot-melt extrusion technique (HME). This technique is widely used to convert 
plastic raw materials into a product of uniform shape and density by heating and 
forcing them through a die, generally employing a rotating screw. It posses many 
advantages such as to overcome mixing and/or compaction problems with powder 
formulations, to eliminate the use of organic solvents. It is a viable technology to 
produce homogeneous drug incorporated polymeric matrices. Many researchers 
proposed HME for the preparation of drug delivery systems, fast dissolving or 
prolonged release formulations to be administered by oral, transdermal, transmucosal 
and transungual routes (Repka et al. 2007, 2012, Loreti et al. 2014, Melocchi et al. 
2015). 
The objective of the present investigation was to develop long acting ocular 
inserts to apply in the posterior segment of the eye. 
 Extrudates containing 3% FA and different polymeric materials (AMYLO, CS, 
CS-MS, HPC) were prepared, properly cut	   to give inserts of suitable size (1.0 x 4.0 x 
12 mm) for ocular application and then undergone to a preliminary evaluation of 
swelling and dissolution properties. The inserts were put in contact with PBS, 
simulating biological fluids, and methylene blue dye solution was added to better 
follow the process. The dissolution process was observed for 5 hours.  As shown in 
Figure 1a, during the first hour of contact, the surface of CS-FA and CS-MS-FA 
inserts appeared hydrate, swelled, partially broken but neither complete dissolution 
nor gel-like transformation had occurred. Conversely, AMYLO-FA surface appeared 
hydrate without swelling and dissolution. After 5 hours, CS-FA appeared too much 
swelled for its placement in the vitreous humour, because it might cause damage to 
the ocular structures. The same behaviour was observed for CS-MS-FA. For these 
reasons both of them were discarded. Based on these first observations, we decided 
to follow the behaviour of AMYLO-FA for further 12 days: during the entire period of 
observation no change had occurred in terms of dissolution and gel-like 
transformation over hydration and light swelling as well illustrated in Figure 1b. 
Starch consists of two polysaccharides: amylose and amylopectin. Amylose is 
made up of α-(1#4) bond glucose molecules, it can exist in a disordered amorphous 
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conformation, and is not soluble in cold water whereas amylopectin is a highly 
branched polymer of glucose and  water soluble.  
Usually, normal starch contains 15-30% amylose, depending on the botanic 
origin, degree of maturity, and growing conditions of the plant. High-amylose starch 
contains 50% or more amylose like the AMYLO used in this study (60% amylose).  
Amylose is able to reduce the crystallinity of amylopectin and how easily water 
can infiltrate the starch. Therefore, a high amount of amylose could decrease the 
degree of hydration. These characteristics might explain the different behaviour of CS 
and AMYLO. 
Previously HPC-FA was selected as the best with respect to a wide range of 
devices tested; in this study AMYLO-FA appeared the best compared to inserts 
based on CS. Drug release performance of AMYLO-FA and HPC-FA inserts was 
comparatively evaluated. The two inserts were submitted to in vitro release study 
using the Gummer-type diffusion cell method (¶ 5.4), maintaining sink conditions 
(continuous receiving phase replacement), to evaluate the device influence on the FA 
release independently to the surrounding environment.  
The release profile of AMYLO-FA and HPC-FA devices up to 52 hours is shown 
in Figure 2 and it indicates that the type of polymer greatly influenced the drug 
release. HPC-FA appeared to release quickly the drug: the main feature in this profile 
was an initial burst effect with approximately 10% of drug released in 2 hours followed 
by a slower release of remaining drug with approximately 89% of drug being released 
over the following 52 hours. The initial burst effect could be attributed to the portion of 
drug present in the surface of the insert, followed by the drug entrapped inside the 
insert. Related to drug release kinetics, the cumulative release data showed linearity 
with good coefficient of regression (r2 = 0.9725) following Higuchi kinetics model. This 
model describes the drug release rate from a matrix, considering the geometry and 
the porous structure of the system. It can be expressed as: 
 
Mt/M∞ = K 𝑡 
 
  where M∞ is the absolute cumulative amount of drug released at infinite time (which 
would be equal to the absolute amount of drug incorporated within the system at time 
t=0), and K is a constant reflecting the design variables of the system. In general 
when applying Higuchi equation to controlled drug delivery system, it is important to 
consider that (a) the initial drug concentration in the system is much higher than the 
solubility of the drug; (b) the suspended drug is in a fine state such that the particles 
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are much smaller in diameter than the thickness of the system; (c) swelling or 
dissolution of the polymer carrier is negligible; (d) the diffusivity of the drug is constant 
and (e) perfect sink conditions are maintained (Siepmann and Peppas, 2001). These 
assumptions are not valid for most controlled drug delivery systems. However, due to 
the simplicity of the Higuchi equation, it is often used to analyse experimental drug 
release data to get a rough idea of the underlying release mechanism. Hence a 
proportionality between the cumulative amount of drug released and the square root 
of time is commonly regarded as an indicator for diffusion-controlled drug release. In 
our case, various phenomena (HPC swelling, polymer dissolution, concentration-
dependent water and drug diffusion etc) seemed coexist and produced an apparent 
square root of time kinetics. Thus the mathematical model indicated that the drug 
release was mainly due to the diffusion and the polymer did not seem able to control 
FA release. 
On the other hand, AMYLO-FA showed a remarkable reduction of FA release: in 
2 hours only the 4% (2-3-fold lower than HPC-FA) of the total drug content was 
released followed by a slowdown (Figure 2) leading to a release of 36.13% of FA at 
52 hours. Also in this case an initial burst effect was noted. Since in 52 hours only 
36.13% of drug was released, the test was continued for 8 days and a slow but 
continuous release was obtained to reach 63.66% of FA released at the end of the 
experiment (Tab. 2). 
Analysing the entire profile, it is possible to note that the release profile can be 
divided in two parts with different rate: in the initial hours (up to 6h), faster drug 
release happened with a rate of 15.65 µg/h (r2=0.9560) followed by a decrease of 
release rate to 4.28 µg/h (r2=0.9369) during the rest of time (up to 7 days). At the 
beginning there is the water uptake from the device with dissolution of drug on the 
surface; it has been previously demonstrated that AMYLO absorbs water up to 50% 
in 2 hours without change in volume. When the process reached the steady-state, a 
controlled drug delivery with zero order kinetics could be hypothesized.  
The different rate on the hydration of inserts surely influenced the FA release: 
while HPC-FA appeared completely solubilized after 5 days, AMYLO-FA inserts 
maintained their shape without dissolution and gel-like transformation over hydration 
and slight swelling even after 12 days. This demonstrated that hydration, swelling and 
erosion/dissolution processes were only marginally influenced by manufacturing 
technique, and the dissolution rate of the drug in the microenviroment within the 
swollen matrix appeared to have a main role on driving drug release. 
Afterwards, with this experiment, we can conclude that HPC-FA does not appear 
suitable to slowly release FA for a long time in the posterior segment of the eye, as 
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we set out to achieve. On the other hand, AMYLO-FA was considered interesting for 
further studies.  
The release rate of FA from AMYLO-FA inserts was also determined using 
another experimental method by referring to Mruthyunjaya et al., 2006 (¶ 5.4). Two 
experimental protocols were performed, the first one replacing totally the receiving 
phase (t.r) every 24 hours, the other every 48 hours. FA release from the AMYLO-FA 
insert for both experiments was linear during the 25-day sampling period as illustrated 
in Figure 4. In similar experiments Jaffe et al (2000) and Mruthyunjaya et al. (2006) 
found the same trend. As summarized in Table 3, the release rates are 26.76 ± 0.44 
and 10.61 ± 0.51 µg/day for a 24 h t.r. and 48 h t.r., respectively. At the end of the 
experiment (25 days), the total FA released were 674.10 ± 20.87 µg and 273.81 ± 
10.08 µg for 24 h and 48 h t.r. respectively. All data are the average of two 
determinations ± standard error (SE). 
The results showed that both the release rate and the amount of drug released 
at the end of the experiment decreased by half when the sampling at longer time (48 
h) was carried out:  so it seemed that the release of drug was mainly influenced and 
driven by the receiving environment (PBS) with respect to the device (insert). In this 
experiment, the change in the receiving phase was very slow to approach the 
biological conditions; in fact, the vitreous humor turnover is considered stagnant; the 
normal vitreous outflow is about of 0.1 µl/min (Park et al, 2005). In addition the 
thermal characteristics of AMYLO-FA insert were studied by using DSC analysis (¶ 
5.6) to characterize the device from a physico-chemical point of view. The 
temperatures corresponding to the thermal transitions are summarized in Table 4 and 
graphically in figure 5 for single pure components (FA powder and AMYLO powder), 
physical mixture (AMYLO-FA physical mixture 97:3; 70:30 and 50:50), unmedicated 
ocular inserts (extruded AMYLO), and medicated ocular inserts (extruded AMYLO-
FA). FA powder showed a thermal transition at 281.79°C corresponding to the melting 
point as reported in literature (Bartolomei et al., 1996).  AMYLO powder had a thermal 
transition at 139.09°C. This transition temperature moved to 170.99 °C when AMYLO 
was subjected to hot-melt extrusion. The combination of AMYLO, FA and extrusion 
technique produced a single peak at 162.02°C; a shift of 20°C of the polymer peak 
was observed and FA peak completely disappeared in this thermogram. To verify the 
influence of the extrusion on the chemical-physical characteristics of polymer, DSC 
analysis of the physical mixtures was performed. AMYLO-FA physical mixture  (97:3, 
the same ratio of the extruded AMYLO-FA) added of 20% glycerol, which is part of 
the composition of the insert extruded, had only a peak of 160.40°C. Even in this case 
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the characteristic transition of FA wasn’t found; this might be due to the modest active 
drug content into the insert. For verifying this hypothesis we have done different ratio 
of polymer-drug physical mixtures. Both AMYLO-FA (50:50) and AMYLO-FA (70:30) 
blends showed the polymer peak at about 149°C, and the typical FA peak at about 
282°C (Tab. 4). This means that our hypothesis might be true, and no alteration of the 
drug had occurred during the extrusion process.  
The DSC analysis suggested that no polymer-drug interaction occurred, and this 
means that the release of the active compound might depend only on the polymer 
modified structure. 
 Further experiments will be performed to optimize the formulation of the insert 
by using in any case the hot-melt extrusion technique. 
The second part of this thesis aimed at tuning up cylindrical matrices by freeze-
drying for administration of vancomycin (VA) in the precorneal area to produce a 
sustained release of drug and consequently to reduce the number of applications. 
The matrices prepared were evaluated in term of drug release rate.  
VA release profile from HPMC-VA was shown in Figure 6: blue line represents 
the results of the experiment where 10 µL MilliQ water was added to hydrate the 
matrix (donor phase) and pink line represents the results obtained hydrating the 
matrix with 50 µL MilliQ water. In the first experiment, the percentage of released VA 
was 8.73% of the total content of the drug, while in the second there was a 2-fold 
increase in drug release (20.29%). In any case HPMC-VA releases the drug very 
slowly, may be due to a drug-polymer interaction during the freeze-drying process. 
DSC analysis of the lyophilized matrix and the single components (VA and HPMC) 
would suggest this hypothesis. In fact freeze dried matrix produced only a peak of 
thermal transition at 147.81 °C while each component had a single peak one (VA) at 
164.7 °C and the other (HPMC) 187.17 °C (Fig.7).  
Further studies should be performed to improve the formulation. 
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Table	  
 
Table 1 - Composition of the inserts under study. 
 
Insert Polymer Excipient FA 
 Molecule %w/w Molecule %w/w %w/w 
AMYLO-FA 
 
Amylo-maize starch 
N-400® 
97 - - 3 
CS-FA Corn starch 97 - - 3 
CS – MS-FA Corn starch 92 Magnesium 
Stearate 
5 3 
HPC-FA Hydroxypropyl 
cellulose 
97 - - 3 
 
 	  
Table 2 - In vitro release parameters of FA from HPC-FA and AMYLO-FA  
using Gummer-type diffusion cells (continuous receiving phase replacement). 
 
Insert FA Released ( % ) 
	   52 h 190 h 
HPC - FA 89.01 ± 5.21 - 
AMYLO - FA 36.13 ± 1.39 63.66 ± 4.18 	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Table 3 - In vitro release parameters of FA from AMYLO-FA using total 
 receiving phase replacement (t.r.). 
 
t.r. Release Rate, 
µg/day 
FA Release 
after 25 days, µg 
24 h 26.76 ± 0.44 674.10 ± 20.87 
48 h 10.61 ± 0.51 273.81 ± 10.08 
 
 
 
Table 4 - DSC analysis data. 
 
Component Polymer Peak T (°C) 
FA Peak T 
(°C) 
FA powder - 281.79 
AMYLO powder 139.09 - 
AMYLO-FA 
physical mixture (97:3)* 160.40 - 
AMYLO-FA 
physical mixture (70:30) 149.64 282.87 
AMYLO-FA 
physical mixture (50:50) 149.59 282.02 
AMYLO Extruded 170.99 - 
AMYLO-FA Extruded 162.02 - 
 
 *containing glycerol 20%.  
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Figure 	  
Figure 1 - Swelling and dissolution properties of extruded inserts in PBS. 
a) until 5 hours; b) until 12 days. 
 
a) 
 
	  	  	  	  
b) 
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